Preanalytical, analytical, gestational and pediatric aspects of the S100B immuno-assays

Bouvier, Damien; Duret, Thomas; Rouzaire, Paul; Jabaudon, Matthieu; Rouzaire, Marion; Nourrisson, Céline; Bourgne, Céline; Pereira, Bruno; Evrard, Bertrand; Sapin, Vincent

doi:10.1515/cclm-2015-0771

Cited by 28 publications

(38 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, data on UCHL-1 and GFAP levels in healthy newborns are not available, so we instead used S100B values which have been reported to decrease from an average of 0.9 to 0.3 ng/ml in the first postnatal months and further decrease to 0.11 ng/ml in adolescence [23]. For healthy adults, S100B levels in serum are below 0.1–0.12 ng/ml [3, 24, 25].…”

Section: Resultsmentioning

confidence: 99%

Improving the clinical management of traumatic brain injury through the pharmacokinetic modeling of peripheral blood biomarkers

Dadas

Washington

Marchi

et al. 2016

Fluids Barriers CNS

View full text Add to dashboard Cite

BackgroundBlood biomarkers of neurovascular damage are used clinically to diagnose the presence severity or absence of neurological diseases, but data interpretation is confounded by a limited understanding of their dependence on variables other than the disease condition itself. These include half-life in blood, molecular weight, and marker-specific biophysical properties, as well as the effects of glomerular filtration, age, gender, and ethnicity. To study these factors, and to provide a method for markers’ analyses, we developed a kinetic model that allows the integrated interpretation of these properties.MethodsThe pharmacokinetic behaviors of S100B (monomer and homodimer), Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase L1 were modeled using relevant chemical and physical properties; modeling results were validated by comparison with data obtained from healthy subjects or individuals affected by neurological diseases. Brain imaging data were used to model passage of biomarkers across the blood–brain barrier.ResultsOur results show the following: (1) changes in biomarker serum levels due to age or disease progression are accounted for by differences in kidney filtration; (2) a significant change in the brain-to-blood volumetric ratio, which is characteristic of infant and adult development, contributes to variation in blood concentration of biomarkers; (3) the effects of extracranial contribution at steady-state are predicted in our model to be less important than suspected, while the contribution of blood–brain barrier disruption is confirmed as a significant factor in controlling markers’ appearance in blood, where the biomarkers are typically detected; (4) the contribution of skin to the marker S100B blood levels depends on a direct correlation with pigmentation and not ethnicity; the contribution of extracranial sources for other markers requires further investigation.ConclusionsWe developed a multi-compartment, pharmacokinetic model that integrates the biophysical properties of a given brain molecule and predicts its time-dependent concentration in blood, for populations of varying physical and anatomical characteristics. This model emphasizes the importance of the blood–brain barrier as a gatekeeper for markers’ blood appearance and, ultimately, for rational clinical use of peripherally-detected brain protein.Electronic supplementary materialThe online version of this article (doi:10.1186/s12987-016-0045-y) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

Improving the clinical management of traumatic brain injury through the pharmacokinetic modeling of peripheral blood biomarkers

Dadas

Washington

Marchi

et al. 2016

Fluids Barriers CNS

View full text Add to dashboard Cite

show abstract

“…Elevated serum S100β in the first three months of life (mean=0.97±0.36µg/L) supports the development of the CNS (46), stimulating neuronal growth (47), glial cell proliferation (48), and increases neuronal survival and maturation (46). In healthy individuals, S100β levels stabilise between ages 2-16y (0.20µg/L) (46). However, elevated levels at other points in life correlate with several neurodegenerative and neuropsychological conditions, with the diagnostic potential of S100β mostly explored in relation to TBI.…”

Section: S100β Origin Distribution and Pathogenesismentioning

confidence: 86%

“…The S100β has dualistic effects, largely dependent upon its local concentration and the stage of human development. Elevated serum S100β in the first three months of life (mean=0.97±0.36µg/L) supports the development of the CNS (46), stimulating neuronal growth (47), glial cell proliferation (48), and increases neuronal survival and maturation (46). In healthy individuals, S100β levels stabilise between ages 2-16y (0.20µg/L) (46).…”

Section: S100β Origin Distribution and Pathogenesismentioning

confidence: 91%

Evaluation of dietary and lifestyle changes as modifiers of S100β levels in Alzheimer’s disease

D’Cunha

McKune

Panagiotakos

et al. 2017

Nutritional Neuroscience

View full text Add to dashboard Cite

There is a significant body of research undertaken in order to elucidate the mechanisms underlying the pathology of Alzheimer's disease (AD), as well as to discover early detection biomarkers and potential therapeutic strategies. One such proposed biomarker is the calcium binding protein S100β, which, depending on its local concentration, is known to exhibit both neurotrophic and neuroinflammatory properties in the central nervous system. At present, relatively little is known regarding the effect of chronic S100β disruption in AD. Dietary intake has been identified as a modifiable risk factor for AD. Preliminary in vitro and animal studies have demonstrated an association between S100β expression and dietary intake which links to AD pathophysiology. This review describes the association of S100β to fatty acids, ketone bodies, insulin, and botanicals as well as the potential impact of physical activity as a lifestyle factor. We also discuss the prospective implications of these findings, including support of the use of a Mediterranean dietary pattern and/or the ketogenic diet as an approach to modify AD risk.

show abstract

“…However, automated assays present better analytical results with regard to precision, linearity, or accuracy, and appear to be a preferable option for S100B measurement. 50,51 Only Babcock et al 41 presented a nonoptimal 100% sensitivity, and a manual assay was used in that study. Other studies 52,53 not included in our meta-analysis (because the authors also included moderate and severe TBI) revealed a nonoptimal sensitivity of ∼75% by using manual assays.…”

Section: Discussionmentioning

confidence: 99%

The Biomarker S100B and Mild Traumatic Brain Injury: A Meta-analysis

Oris¹,

Pereira²,

Durif³

et al. 2018

Pediatrics

Self Cite

View full text Add to dashboard Cite

show abstract

Preanalytical, analytical, gestational and pediatric aspects of the S100B immuno-assays

Cited by 28 publications

References 20 publications

Improving the clinical management of traumatic brain injury through the pharmacokinetic modeling of peripheral blood biomarkers

Improving the clinical management of traumatic brain injury through the pharmacokinetic modeling of peripheral blood biomarkers

Evaluation of dietary and lifestyle changes as modifiers of S100β levels in Alzheimer’s disease

The Biomarker S100B and Mild Traumatic Brain Injury: A Meta-analysis

Contact Info

Product

Resources

About